focus -WSS

focus

author：comprehensive 2025-09-06 07:17:26 - browse：12992

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： U.K. officials, researchers try to ease path for bespoke genetic treatments

entertainment

WSS

6 surprising facts about sugar

Prior authorization reform is both possible and imperative

Mirador, a new biotech startup, launches with $400 million

Maisha Meds is a PBM, but don't call it that

Cardiologists urge adding sexual orientation, gender identity to health records

Prior authorization reform is both possible and imperative

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Continuity nursing helped my family in our darkest PICU moments

Prior authorization reform is both possible and imperative

Hollywood unions extend contract negotiations for actors

Printout prescription drug information shouldn’t go digital

Drug repurposing or repositioning? The language matters

To bolster infectious disease surveillance, genomics powerhouses team up

The high cost of giving birth even with insurance

Dana Farber says 6 studies to be retracted and 31 corrected

Heart attack and stroke risk calculators need revising

Microsoft launches AI tool for clinical documentation through Epic

focus

CRISPR technology availability, affordability needs to be expanded

Medicare bonuses could stop drug shortages under Senate plan

Future doctors need a strong humanities education

CRISPR technology availability, affordability needs to be expanded

Printout prescription drug information shouldn’t go digital

Medical devices makers are asking for forgiveness, not permission

leisure time

entertainment

Wikipedia

Wikipedia